sn-Glycero-3-phosphocholine
| Code | Size | Price |
|---|
| TAR-T4439-1g | 1g | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Glycerylphosphorylcholine is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have a potential for the treatment of Alzheimer's disease and dementia. Glycerylphosphorylcholine rapidly delivers choline to the brain across the blood?brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter. It is a non-prescription drug in most countries due to its Generally Recognised As Safe (GRAS) status [1]. Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer's disease. An Italian multicentre clinical trial on 2, 044 patients suffering from recent stroke were supplied Glycerylphosphorylcholine in doses of 1, 000 mg/day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance [2].
CAS:
28319-77-9
Formula:
C8H20NO6P
Molecular Weight:
257.223
Pathway:
Neuroscience; Metabolism
Purity:
0.9853
SMILES:
C[N+](C)(C)CCOP([O-])(=O)OC[C@H](O)CO
Target:
Endogenous Metabolite; AChE
References
Parnetti L, et al. Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation J Neurol Sci. 2007 Jun 15;257(1-2):264-9.
Barbagallo Sangiorgi G, et al. Alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann NY Acad Sci 1994; 717:253-69.